Roivant Sciences Ltd
ROIVHealthcare|Biotechnology|UK
$35.98
-0.86 (-2.34%)
Tangible Book
$6.29
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04351243 A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | COVID-19 | P2 | Completed | 227 | RCT, Double-blind | Gimsilumab, Placebo |
| NCT02611921 Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder | Autism Spectrum Disorder | P1 | Completed | 21 | RCT, Double-blind | Ketamine, Placebo |